215 related articles for article (PubMed ID: 32392629)
1. Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers.
Sanchez Calle A; Yamamoto T; Kawamura Y; Hironaka-Mitsuhashi A; Ono M; Tsuda H; Shimomura A; Tamura K; Takeshita F; Ochiya T; Yamamoto Y
Mol Oncol; 2020 Sep; 14(9):2271-2287. PubMed ID: 32392629
[TBL] [Abstract][Full Text] [Related]
2. lncRNA NR2F1-AS1 promotes breast cancer angiogenesis through activating IGF-1/IGF-1R/ERK pathway.
Zhang Q; Li T; Wang Z; Kuang X; Shao N; Lin Y
J Cell Mol Med; 2020 Jul; 24(14):8236-8247. PubMed ID: 32548873
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and ΔNp63.
Liu Y; Zhang P; Wu Q; Fang H; Wang Y; Xiao Y; Cong M; Wang T; He Y; Ma C; Tian P; Liang Y; Qin LX; Yang Q; Yang Q; Liao L; Hu G
Nat Commun; 2021 Sep; 12(1):5232. PubMed ID: 34475402
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA and LncRNA Expression Profiles in Human Estrogen Receptor Positive Breast Cancer.
Shao X; Huang P; Shi L; Lei L; Cao W; Chen Z; Wang X; Zheng Y
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775882
[TBL] [Abstract][Full Text] [Related]
5. A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen.
Wang K; Li J; Xiong YF; Zeng Z; Zhang X; Li HY
Sci Rep; 2018 Feb; 8(1):3179. PubMed ID: 29453409
[TBL] [Abstract][Full Text] [Related]
6. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer.
Kim RS; Avivar-Valderas A; Estrada Y; Bragado P; Sosa MS; Aguirre-Ghiso JA; Segall JE
PLoS One; 2012; 7(4):e35569. PubMed ID: 22530051
[TBL] [Abstract][Full Text] [Related]
7. LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis.
Liu SQ; Zhou ZY; Dong X; Guo L; Zhang KJ
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32538432
[TBL] [Abstract][Full Text] [Related]
8. The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer.
Fukuoka M; Ichikawa Y; Osako T; Fujita T; Baba S; Takeuchi K; Tsunoda N; Ebata T; Ueno T; Ohno S; Saitoh N
Cancer Sci; 2022 Jul; 113(7):2336-2351. PubMed ID: 35415910
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Barwal TS; Sharma U; Bazala S; Singh I; Jain M; Prakash H; Shekhar S; Sandberg EN; Bishayee A; Jain A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920789
[TBL] [Abstract][Full Text] [Related]
10. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis.
Guo F; Fu Q; Wang Y; Sui G
J Cell Mol Med; 2019 Sep; 23(9):5907-5919. PubMed ID: 31304680
[TBL] [Abstract][Full Text] [Related]
12. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
[TBL] [Abstract][Full Text] [Related]
13.
Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W
Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278
[TBL] [Abstract][Full Text] [Related]
14. Opposite trends of GAS6 and GAS6-AS expressions in breast cancer tissues.
Lavasani A; Hussen BM; Taheri F; Sattari A; Yousefi H; Omrani MD; Nazer N; Ghafouri-Fard S; Taheri M
Exp Mol Pathol; 2021 Feb; 118():104600. PubMed ID: 33359886
[TBL] [Abstract][Full Text] [Related]
15. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
Niknafs YS; Han S; Ma T; Speers C; Zhang C; Wilder-Romans K; Iyer MK; Pitchiaya S; Malik R; Hosono Y; Prensner JR; Poliakov A; Singhal U; Xiao L; Kregel S; Siebenaler RF; Zhao SG; Uhl M; Gawronski A; Hayes DF; Pierce LJ; Cao X; Collins C; Backofen R; Sahinalp CS; Rae JM; Chinnaiyan AM; Feng FY
Nat Commun; 2016 Sep; 7():12791. PubMed ID: 27666543
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNAs as prognostic markers in human breast cancer.
Liu H; Li J; Koirala P; Ding X; Chen B; Wang Y; Wang Z; Wang C; Zhang X; Mo YY
Oncotarget; 2016 Apr; 7(15):20584-96. PubMed ID: 26942882
[TBL] [Abstract][Full Text] [Related]
17. A prognostic eight-lncRNA expression signature in predicting recurrence of ER-positive breast cancer receiving endocrine therapy.
Tang J; Cui Q; Zhang D; Kong D; Liao X; Ren J; Gong Y; Wu G
J Cell Physiol; 2020 May; 235(5):4746-4755. PubMed ID: 31663114
[TBL] [Abstract][Full Text] [Related]
18. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
Liu D
Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
[TBL] [Abstract][Full Text] [Related]
19. Selective expression of long non-coding RNAs in a breast cancer cell progression model.
Tracy KM; Tye CE; Page NA; Fritz AJ; Stein JL; Lian JB; Stein GS
J Cell Physiol; 2018 Feb; 233(2):1291-1299. PubMed ID: 28488769
[TBL] [Abstract][Full Text] [Related]
20. LincIN, a novel NF90-binding long non-coding RNA, is overexpressed in advanced breast tumors and involved in metastasis.
Jiang Z; Slater CM; Zhou Y; Devarajan K; Ruth KJ; Li Y; Cai KQ; Daly M; Chen X
Breast Cancer Res; 2017 May; 19(1):62. PubMed ID: 28558830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
